EVOLUTION OF CANCER TREATMENT COST IN THE LAST 36 MONTHS: AN ANALYSIS FROM A HEALTH PAYER PERSPECTIVE IN BRAZIL

被引：0
|
作者：
Reis Neto, J. P. [1 ]
Busch, J. [2 ]
机构：
[1] CAPESESP, Rio De Janeiro, Brazil
[2] Souza Marques Univ, Rio De Janeiro, RJ, Brazil
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
RWD159
引用
收藏
页码：S391 / S391
页数：1
相关论文
共 50 条
  • [21] Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective
    Cicin, Irfan
    Oksuz, Ergun
    Karadurmus, Nuri
    Malhan, Simten
    Gumus, Mahmut
    Yilmaz, Ulku
    Cansever, Levent
    Cinarka, Halit
    Cetinkaya, Erdogan
    Kiyik, Murat
    Ozet, Ahmet
    HEALTH ECONOMICS REVIEW, 2021, 11 (01)
  • [22] BUDGET-IMPACT ANALYSIS (BIA) OF OBESITY FROM A HEALTHCARE PAYER PERSPECTIVE IN BRAZIL
    Busch, J.
    Reis Neto, J. P.
    VALUE IN HEALTH, 2019, 22 : S595 - S595
  • [23] BUDGET IMPACT ANALYSIS OF ADOPTING THE LAPAROSCOPIC SURGERY APPROACH IN PATIENTS WITH COLORECTAL CANCER FROM THE PRIVATE PAYER PERSPECTIVE IN BRAZIL
    Saggia, M.
    Follador, W.
    Valencia, J.
    VALUE IN HEALTH, 2016, 19 (03) : A300 - A300
  • [24] Cost Comparison of Treatment Alternatives for Pleural Effusion and Ascites from a Payer Perspective: Are There Cost Savings from Indwelling Catheters?
    Siefen, Ann-Cathrine
    Eilers, Leonie
    Baltin, Christoph T.
    Kron, Florian
    JOURNAL OF PALLIATIVE MEDICINE, 2023, 26 (11) : 1510 - 1520
  • [25] BUDGET IMPACT OF INTRODUCING SECUKINUMAB IN THE TREATMENT OF ANKYLOSING SPONDYLITIS FROM THE PRIVATE PAYER PERSPECTIVE IN BRAZIL
    Tozato, C.
    Huerta, C.
    Suzuki, C.
    Lopes, N.
    VALUE IN HEALTH, 2018, 21 : S291 - S291
  • [26] COST-EFFECTIVENESS ANALYSIS OF THREE MONTHS TREATMENT WITH FESOTERODINE COMPARED TO GENERIC OXYBUTYNIN EXTENDED-RELEASE IN WOMEN WITH URINARY INCONTINENCE FROM A THIRD PARTY PAYER PERSPECTIVE
    Blaser, D. A.
    Kohn, M. J.
    Ousterhout, M.
    VALUE IN HEALTH, 2010, 13 (03) : A78 - A79
  • [27] Cost minimization and budget impact analysis of rituximab versus infliximab, adalimumab, etanercept and abatacept in rheumatoid arthritis from a payer perspective in Brazil
    Saggia, M. G.
    Santos, E. A.
    Nasciben, V
    VALUE IN HEALTH, 2008, 11 (03) : A260 - A260
  • [28] COST ANALYSIS OF ADJUNCTIVE HYDROCORTISONE THERAPY FOR SEPTIC SHOCK FROM THE US PAYER PERSPECTIVE
    Oh, Mok
    Patanwala, Asad
    Alsaid, Nimer
    Almutairi, Abdulaali
    Abraham, Ivo
    Erstad, Brian
    CRITICAL CARE MEDICINE, 2019, 47
  • [29] Use of health resources in lung cancer patients: A Brazilian analysis in the private payer perspective
    Stefani, S.
    Brandalise, P.
    VALUE IN HEALTH, 2008, 11 (03) : A57 - A58
  • [30] ANALYSIS OF COST EFFECTIVENESS AND COST UTILITY OF THE USE OF DACLATASVIR plus ASUNAPREVIR IN THE TREATMENT OF PATIENTS WITH HEPATITIS C IN COLOMBIA, FROM THE PERSPECTIVE OF THE THIRD PAYER
    Marrugo Pigueroa, R. D.
    Romero Prada, M. E.
    Acero Acero, G.
    Alfonso Quinones, P. A.
    VALUE IN HEALTH, 2015, 18 (07) : A871 - A871
12345